Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 26, 2023

BUY
$161.33 - $204.36 $387,192 - $490,464
2,400 Added 77.42%
5,500 $999,000
Q3 2022

Oct 28, 2022

BUY
$123.79 - $277.42 $383,749 - $860,002
3,100 New
3,100 $697,000

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track Nj State Employees Deferred Compensation Plan Portfolio

Follow Nj State Employees Deferred Compensation Plan and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nj State Employees Deferred Compensation Plan, based on Form 13F filings with the SEC.

News

Stay updated on Nj State Employees Deferred Compensation Plan with notifications on news.